FOR IMMEDIATE RELEASE
TechniScan Elects Joe Pepper, Ph.D. as Chairman of the Board
SALT LAKE CITY (December 15, 2010) -- TechniScan (OTC Bulletin Board: TSNI), a medical device company engaged in the development and commercialization of an automated 3D breast ultrasound imaging system, announced that Joe Pepper, Ph.D. has been elected as chairman of the board of directors of TechniScan.
“As a member of the current board of directors, Joe Pepper has already made significant contributions in helping us bring TechniScan's Warm Bath Ultrasound closer to commercialization, and his leadership and experience in the field will further benefit the company as he takes over as the chairman," said outgoing Board Chairman Ken Hungerford.
Hungerford has served as chairman since the company went public in the fall of 2009, and he will continue to serve on the board’s executive committee along with Pepper and TechniScan CEO David Robinson.
With 28 years in the medical device field, Pepper currently serves as a consultant to medical device start-ups. Formerly he served as CEO of U-Systems, Inc., a privately-backed start-up that developed automated ultrasound for the early detection of breast cancer in women with dense breast tissue. He was CEO for OEC Medical Systems, a NYSE-traded, mobile fluoroscopic imaging equipment manufacturer until it was sold to GE Healthcare. He spent 15 years with The BOC Group, Plc., where he served as president of its subsidiary Ohmeda Medical Devices, which was responsible for international selling and distribution of medical devices, and as president of Ohmeda Medical Equipment.
Pepper has been a member of TechniScan’s board of directors since October 2009. He has a BS/MS in Engineering Science from Florida State University, a Ph.D. in Mechanical Engineering from Stanford University and an MBA from The Harvard Business School.
"I am excited about the opportunity to add my knowledge and perspective to TechniScan, a company I have admired for quite some time. Its 3D ultrasound images have impressive specificity and the potential to change the way that radiologists and oncologists detect cancer in the breast. The TechniScan management team has outstanding depth and diversity of perspective. I am honored to be a part of the group, and I feel confident that with our collective experience, we can make TechniScan’s imaging modality the premier method for breast diagnostics,” said Pepper.
“It’s a pleasure to be working with a person of Joe’s professional caliber and look forward to working to effectively execute our business plan with him,” Robinson said.
TechniScan, Inc. is a medical device company engaged in the development and commercialization of a non-invasive imaging tool designed to provide physicians with automated ultrasound images of the human breast. TechniScan's Warm Bath Ultrasound™ (WBU™) imaging device is limited by U.S. law to investigational use unless, and until, cleared by the FDA. For more information, please visit www.tsni.com.
Forward Looking Statements
Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be identified by the use of words such as "anticipate, "believe," "expect," "future," "may," "will," "would," "should," "plan," "projected," "potential," "intend," and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of TechniScan, Inc. (the "company") to be materially different from those expressed or implied by such forward-looking statements. The company’s future operating results are dependent upon many factors, including risk factors discussed in the company’s periodic filings with the Securities and Exchange Commission, which are available for review at www.sec.gov, including the company’s Annual Report on Form 10-K filed on March 22, 2010. The company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.